スケジュール Invesco Nasdaq Biotechnology ETF
簡単なスケジュール
拡張スケジュール
主なパラメーター
| 10夏の収益性 | 0 |
| 3夏の収益性 | -1.82 |
| 5夏の収益性 | 0 |
| Webサイト | システム |
| isinコード | US46138G5999 |
| カントリーイソ | US |
| セグメント | Equity: U.S. Pharma, Biotech & Life Sciences |
| トップ10発行者、% | 46.43 |
| ベースの日付 | 2021-06-09 |
| ベータ | 1.06 |
| 企業の数 | 48 |
| 国 | USA |
| 地域 | North America |
| 地域 | U.S. |
| 平均P/BV | 3.66 |
| 平均P/E | -32.01 |
| 平均P/s | 4.82 |
| 年間収益性 | 40.98 |
| 戦略 | Exchange-specific |
| 所有者 | Invesco |
| 手数料 | 0.19 |
| 神の収益性 | 0.69 |
| 索引 | NASDAQ / Biotechnology |
| 資産サイズ | Large-Cap |
| 資産タイプ | Equity |
| 通貨 | usd |
| 集中 | Health Care |
| その日の変化 | 0% 29.96 $ |
| 今週の変化 | +0.27% 29.88 $ |
| 1か月後に変更されます | +1.84% 29.42 $ |
| 3か月で変化します | +4.65% 28.629 $ |
| 6か月で変化します | +15.88% 25.855 $ |
| 今年の変更 | +40.98% 21.251 $ |
| 年の初めから変化します | +3.38% 28.98 $ |
サブスクリプションを支払います
企業とポートフォリオの分析のためのより多くの機能とデータは、サブスクリプションで入手できます
トップ企業
| 名前 | 業界 | 共有, % | P/BV | P/S | P/E | EV/Ebitda | 配当利回り | |
| #1 |
Vertex |
Healthcare | 8.7193 | 6.28 | 9.35 | -186.72 | 205.99 | 0 |
| #2 |
Gilead Sciences |
Healthcare | 7.7858 | 6 | 4.02 | 240.57 | 29.81 | 2.59 |
| #3 |
Amgen |
Healthcare | 7.7143 | 23.87 | 4.2 | 34.3 | 14.11 | 3.17 |
| #4 |
Regeneron |
Healthcare | 5.9529 | 2.75 | 5.69 | 18.33 | 15.25 | 0.22 |
| #5 |
AstraZeneca PLC |
Healthcare | 4.1131 | 10.03 | 7.58 | 58.27 | 28.15 | 3.79 |
| #6 |
Alnylam Pharmaceuticals, Inc. |
Healthcare | 3.9854 | 233.68 | 13.4 | -197.3 | -170.29 | 0 |
| #7 |
Insmed Incorporated |
Healthcare | 2.7697 | 39.59 | 31.06 | -21.8 | -13.25 | 0 |
| #8 |
Biogen |
Healthcare | 1.9882 | 1.31 | 2.26 | 13.43 | 9.25 | 0 |
| #9 |
argenx SE |
Healthcare | 1.734 | 7.35 | 18.45 | 48.51 | 370.32 | 0 |
| #10 |
Illumina |
Healthcare | 1.6675 | 8.95 | 4.86 | -12.66 | -31.36 | 0 |
似ている ETF
管理会社のその他のETF
| 名前 | クラス | カテゴリ | 手数料 | 年間収益性 |
| Equity | 0.2 | 14.89 | ||
| Equity | 0.2 | 14.21 | ||
| Equity | 0.02 | 13.52 | ||
| Equity | 0.15 | 13.76 | ||
| Equity | 0.15 | 14.3 | ||
| Equity | 0.15 | 12.63 | ||
| Bond | 0.65 | -1.34 | ||
| Equity | 0.39 | 20.82 | ||
| Equity | 0.29 | 10.26 | ||
| Commodity | 0.59 | 12.79 | ||
| Equity | 0.2 | 14.64 | ||
| Bond | 0.1 | -0.17 | ||
| Equity | 0.4 | 19.04 | ||
| Bond | 0.1 | -0.14 | ||
| Equity | 0.58 | 31.51 | ||
| Bond | 0.1 | 0.22 | ||
| Equity | 0.39 | 17.93 | ||
| Equity | 0.3 | 10.7 | ||
| Bond | 0.28 | 5.82 | ||
| Equity | 0.34 | 15.9 | ||
| Equity | 0.39 | 21.14 | ||
| Equity | 0.6 | 4.96 | ||
| Equity | 0.35 | 22.85 | ||
| Bond | 0.23 | 0.48 | ||
| Bond | 0.1 | 0.69 | ||
| Commodity | 0.85 | 14.6 | ||
| Equity | 0.45 | 31.52 | ||
| Bond | 0.08 | -0.12 | ||
| Multi-Asset | 0.5 | 1.48 | ||
| Bond | 0.1 | 1.25 |
説明 Invesco Nasdaq Biotechnology ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the index. Strictly in accordance with its guidelines and mandated procedures, Nasdaq compiles the underlying index, which is a modified market capitalization weighted index that is designed to measure the performance of securities listed on the Nasdaq Stock Market that are classified as either biotechnology or pharmaceutical companies. The index may include securities of large-, mid- and small-capitalization companies. The fund is non-diversified.
ソースに基づいています: porti.ru

MAX













